Roche's new breast cancer drug (Giredestrant or similar) has blockbuster potential because it targets hormone receptor positive breast cancer (70% of patients), reduces risk of death/recurrence by over 30%, is well-tolerated, and is the first new hormone treatment in over 20 years. The market overreacted to trial data, and the drug will be one of Roche's biggest medicines.